top of page
Treating fibrotic disease and restoring organ function
About
Kleis develops oral therapies that stop fibrosis at its source, tackling a process that drives many chronic, life‑limiting diseases.
TG2 proteins resist natural breakdown and build up in tissues; a hallmark of conditions like fibrostenosing Crohn’s, cardiac fibrosis, chronic kidney disease and Idiopathic pulmonary fibrosis (IPF).
.png)
The outlook for patients with these diseases is either surgery or organ failure leading to transplant or death. Outcomes affecting hundreds of millions worldwide.
Kleis is working towards a future where fibrosis can be reversed and people can live longer, healthier lives.
Partners
bottom of page